InfertilityWCFCNCT00716118
Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.
An observational study of Infertility, run by West Coast Fertility Centers at 1 site in United States.
Trial summary
Our aims is to document the possible effect of cryo- preservation at the meiotic spindle and mitochondrial levels. Read more about this study
- Who is it for?
- Ages 21 to 37 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Infertility
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2008to Jul 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 37 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Women of reproductive age who undergo controlled ovarian hyperstimulation (COH) for IVF are recruited for this study.
Who may be able to join
- To be eligible for inclusion into this study, each subject must satisfy the following criteria:
- Participants must be aged 21 to 35 years
- Body mass index (BMI) < 38.
- Serum results for cycle day 3 FSH <10 mIU/ml.
- Be willing and able to comply with the protocol for the duration of the study.
- Have voluntarily provided written informed consent under WIRB, prior to any study-related procedure that is not part of normal medical care, with the understanding that the subjects may withdraw consent anytime without prejudice to their future medical care.
- Have passed a psychological and physical screening.
Who cannot join
- A patient may NOT be entered into the study if she presents with ANY of the following criteria:
- Clinically significant systemic disease.
- Known endometriosis Grade III - IV (ASRM classification).
- Any previous cycle indicating a low response to gonadotropin stimulation (defined as retrieval of < 10 eggs at retrieval)
- Previous ovarian surgery
- Known allergy or hypersensitivity to recombinant gonadotropin preparations or any other study-related medications.
Show all 11Show fewer
- Known current substance abuse.
- Simultaneous participation in another clinical trial.
- Current smoker.
- An extrauterine pregnancy within the last 3 months before OCP treatment commences.
- Previous participation in similar study at different centers.
Trial locations and contacts
1 site in 1 country.
United States1 site
West Coast Fertility Centers
Fountain Valley, California, 92708
About this study
Official title: Oocytes Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.
Our aims is to document the possible effect of cryo- preservation at the meiotic spindle and mitochondrial levels.
Read the detailed description
The cryopreservation of oocytes (OC) has broad applications in the field of reproductive endocrinology for the management of clinical problems in both fertile and infertile patients. For example, young fertile women who are diagnosed with malignancies may freeze their oocytes before initiating potentially toxic radiation or chemical cancer therapy which may render them sterile.
Using the OC technology, we have established a frozen oocyte bank using healthy, compensated egg donors who have been pre- screened using FDA criteria. Following an appropriate quarantine time, oocytes can be thawed and offered to women diagnosed with premature ovarian failure or diminished ovarian reserve. This application of OC has already shown promise by eliminating the logistical and clinical complications associated with traditional oocyte donation using fresh oocytes from donors.
From the societal perspective, cryopreservation of surplus oocytes in an IVF cycle may remove some of the social and moral objections surrounding embryo cryopreservation. Currently, our frozen oocyte pregnancy rate (56%) is equivalent to our frozen embryo pregnancy rate (45%). Patients, who have completed their families, find it easier to discard oocytes versus embryos.
Finally, women who make a personal choice to delay childbearing may be offered the option to preserve their oocytes with the potential for later use.
The two distinct techniques currently being used for oocyte cryopreservation are: 1) controlled-rate freezing and 2) vitrification. Controlled-rate freezing shares some similarities with the basic technology employed for embryo cryopreservation in nearly every IVF program. The technique involves the slow freezing of embryos in cryoprotectant solutions, often combined with a computer-controlled freezer to regulate temperature changes. Attempts to improve our understanding of oocyte cryobiology have been mostly empirical using trial and error. Only limited experience has been gained by adopting scientific models able to predict the effect of "cryo" stress imposed on oocytes using various freezing methods (Fuller and Paynter, 2004; Paynter, 2005). In the absence of properly designed studies, advances in clinical experience with oocyte freezing have been very limited. One of the major obstacles to the implementation of oocyte freezing had been the inability to achieve reproducible high survival rates owing to an important effect on the intracellular organelles. For example, due to its sensitivity at low temperature, the metaphase II spindle has always been considered susceptible to structural alterations which potentially might interfere with normal chromosome segregation at meiosis II. Additionally, the essential role of mitochondria in normal cell function, fertilization and early embryo development has previously been described (Jones et al., 2004).
Our recently developed modified freeze-thaw protocol has consistently shown high recovery rates, leading to optimism that oocyte storage could at last become available in clinical practice. But it remains to be demonstrated that excellent post-thaw survival coincides with cellular integrity and unaltered developmental competence. Therefore, prior to recommending the adoption of oocyte cryopreservation, one of our aims is to document the possible effect of cryo- preservation at the meiotic spindle and mitochondrial levels. An important aim of our study is to assess the post-thaw viability and organelle integrity of oocytes using: 1) a conservative technique [PolScope analysis of meiotic spindle] and 2) a non-conservative technique [Fluorescence microscopy analysis of the meiotic spindle and mitochondria] using our oocyte cryopreservation protocol.
Continuing development in freezing technology is occurring rapidly. It can be anticipated that in the near future, egg freezing will become as successful as embryo cryopreservation. Finally, as more clinical experience with egg freezing accumulates, acceptable outcome data will determine the future of egg freezing. Until then, oocyte cryopreservation should be used in carefully selected clinical cases with full disclosure to the patient regarding risks and limited success rates.
- Conditions
- Infertility
- Keywords
- Oocyte Cryopreservation, Slow-Freeze, Egg Freezing, Meiotic Spindle, Mitochondria, Human Oocytes Freezing.
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | IVF patients. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To document the freeze/thaw survival rates of human oocytes and to compare the structure changes in their meiotic spindle and mitochondria before and after cryopreservation.
Measured: When study complete
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2008 (estimated)
- Study startJul 2008
- Primary completionJul 2010
- Study completionJul 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West Coast Fertility Centers
- Sponsor type
- University, hospital or other
- Investigators
- David G Diaz, MD, Principal investigator, West Coast Fertility Centers
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00716118
- Sponsor's protocol ID
- 2008-02
- Acronym
- WCFC
- Status last verified
- Jan 2011
- First submitted
- 11 Jul 2008
- Last updated
- 6 Jan 2011
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oocytes Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.
- ClinicalTrials.gov ID
- NCT00716118
- Acronym / sponsor ID
- WCFC / 2008-02
- Conditions
- Infertility
- Keywords
- Oocyte Cryopreservation, Slow-Freeze, Egg Freezing, Meiotic Spindle, Mitochondria, Human Oocytes Freezing.
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- West Coast Fertility CentersUniversity, hospital or other
- Study start
- Jul 2008
- Primary completion
- Jul 2010 (actual)
- Study completion
- Jul 2010 (actual)
- First posted
- 16 Jul 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our aims is to document the possible effect of cryo- preservation at the meiotic spindle and mitochondrial levels.
Detailed description
The cryopreservation of oocytes (OC) has broad applications in the field of reproductive endocrinology for the management of clinical problems in both fertile and infertile patients. For example, young fertile women who are diagnosed with malignancies may freeze their oocytes before initiating potentially toxic radiation or chemical cancer therapy which may render them sterile.
Using the OC technology, we have established a frozen oocyte bank using healthy, compensated egg donors who have been pre- screened using FDA criteria. Following an appropriate quarantine time, oocytes can be thawed and offered to women diagnosed with premature ovarian failure or diminished ovarian reserve. This application of OC has already shown promise by eliminating the logistical and clinical complications associated with traditional oocyte donation using fresh oocytes from donors.
From the societal perspective, cryopreservation of surplus oocytes in an IVF cycle may remove some of the social and moral objections surrounding embryo cryopreservation. Currently, our frozen oocyte pregnancy rate (56%) is equivalent to our frozen embryo pregnancy rate (45%). Patients, who have completed their families, find it easier to discard oocytes versus embryos.
Finally, women who make a personal choice to delay childbearing may be offered the option to preserve their oocytes with the potential for later use.
The two distinct techniques currently being used for oocyte cryopreservation are: 1) controlled-rate freezing and 2) vitrification. Controlled-rate freezing shares some similarities with the basic technology employed for embryo cryopreservation in nearly every IVF program. The technique involves the slow freezing of embryos in cryoprotectant solutions, often combined with a computer-controlled freezer to regulate temperature changes. Attempts to improve our understanding of oocyte cryobiology have been mostly empirical using trial and error. Only limited experience has been gained by adopting scientific models able to predict the effect of "cryo" stress imposed on oocytes using various freezing methods (Fuller and Paynter, 2004; Paynter, 2005). In the absence of properly designed studies, advances in clinical experience with oocyte freezing have been very limited. One of the major obstacles to the implementation of oocyte freezing had been the inability to achieve reproducible high survival rates owing to an important effect on the intracellular organelles. For example, due to its sensitivity at low temperature, the metaphase II spindle has always been considered susceptible to structural alterations which potentially might interfere with normal chromosome segregation at meiosis II. Additionally, the essential role of mitochondria in normal cell function, fertilization and early embryo development has previously been described (Jones et al., 2004).
Our recently developed modified freeze-thaw protocol has consistently shown high recovery rates, leading to optimism that oocyte storage could at last become available in clinical practice. But it remains to be demonstrated that excellent post-thaw survival coincides with cellular integrity and unaltered developmental competence. Therefore, prior to recommending the adoption of oocyte cryopreservation, one of our aims is to document the possible effect of cryo- preservation at the meiotic spindle and mitochondrial levels. An important aim of our study is to assess the post-thaw viability and organelle integrity of oocytes using: 1) a conservative technique [PolScope analysis of meiotic spindle] and 2) a non-conservative technique [Fluorescence microscopy analysis of the meiotic spindle and mitochondria] using our oocyte cryopreservation protocol.
Continuing development in freezing technology is occurring rapidly. It can be anticipated that in the near future, egg freezing will become as successful as embryo cryopreservation. Finally, as more clinical experience with egg freezing accumulates, acceptable outcome data will determine the future of egg freezing. Until then, oocyte cryopreservation should be used in carefully selected clinical cases with full disclosure to the patient regarding risks and limited success rates.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –IVF patients. |
Who may qualify
- Ages
- 21 to 37 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Women of reproductive age who undergo controlled ovarian hyperstimulation (COH) for IVF are recruited for this study.
Key inclusion criteria (7 listed)
- To be eligible for inclusion into this study, each subject must satisfy the following criteria:
- Participants must be aged 21 to 35 years
- Body mass index (BMI) < 38.
- Serum results for cycle day 3 FSH <10 mIU/ml.
- Be willing and able to comply with the protocol for the duration of the study.
Key exclusion criteria (11 listed)
- A patient may NOT be entered into the study if she presents with ANY of the following criteria:
- Clinically significant systemic disease.
- Known endometriosis Grade III - IV (ASRM classification).
- Any previous cycle indicating a low response to gonadotropin stimulation (defined as retrieval of < 10 eggs at retrieval)
- Previous ovarian surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To document the freeze/thaw survival rates of human oocytes and to compare the structure changes in their meiotic spindle and mitochondria before and after cryopreservation.
Time frame: When study complete
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2011.
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David G Diaz, MD principal investigator
West Coast Fertility Centers
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infertility, run by West Coast Fertility Centers at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jan 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To document the freeze/thaw survival rates of human oocytes and to compare the structure changes in their meiotic spindle and mitochondria before and after cryopreservation. (time frame: When study complete). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2011.